Refractive outcomes after trabecular microbypass stent with cataract extraction in open-angle glaucoma
Received 24 February 2019
Accepted for publication 8 May 2019
Published 25 July 2019 Volume 2019:13 Pages 1331—1340
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Rachel A Scott,1 Tanner J Ferguson,2 John D Stephens,3 John P Berdahl3
1Baylor College of Medicine, Houston, TX, USA; 2Sanford School of Medicine, University of South Dakota, Vermillion, SD, USA; 3Vance Thompson Vision, Sioux Falls, SD, USA
Purpose: To evaluate the impact of trabecular microbypass stents combined with cataract surgery on refractive outcomes in patients with open-angle glaucoma (OAG).
Setting: Private practice, Sioux Falls, South Dakota, USA.
Design: Retrospective, comparative case series.
Methods: Eyes with OAG had implantation of trabecular microbypass stents with concomitant cataract surgery. The unmatched control group comprised eyes that underwent only cataract extraction. Data were collected preoperatively and postoperatively for 6 months. Data included spherical equivalent (SE), astigmatic error, intraocular pressure (IOP), and number of glaucoma medications.
Results: The series included 76 consecutive OAG eyes with combined cataract plus trabecular microbypass stent and 50 consecutive non-OAG eyes with cataract surgery only. SE outcomes were equivalent between the groups (P<0.001). For the combined and cataract-only groups respectively, 46% vs 52% had SEs within 0.25 D of the target, 80% vs 80% within 0.50 D, and 95% vs 94% within 1.00 D. Astigmatism outcomes did not significantly differ between the groups (P>0.05). As for magnitude of astigmatism in the combined and cataract only groups respectively, 51% vs 32% were within 0.5 D, 75% vs 66% within 1.0 D, 87% vs 82% within 1.5 D, and 89% vs 94% within 2.0 D. In the OAG combined–surgery group, mean intraocular pressure reduction was 3.4 mmHg (P<0.0001) at 1 month postoperatively, 4.0 mmHg (P<0.0001) at 3 months, and 3.4 mmHg (P<0.01) at 6 months. Mean decrease in number of glaucoma medications was 0.4 (P<0.05) at 1 month, 0.7 (p<0.0001) at 3 months, and 0.9 (P<0.001) at 6 months.
Conclusion: The results of this study suggest the trabecular microbypass stent is a refractively neutral device.
Keywords: MIGS, glaucoma, refractive, outcomes, cataract surgery
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]